Innovation1 Biotech Inc 's ROA from the second quarter of 2024 to the second quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Innovation1 Biotech Inc 's ROA in the second quarter of 2024?
Innovation1 Biotech Inc recorded a cumulative net loss of $-5 million during 12 months ending in the second quarter of 2024, resulting in a negative return on assets (ROA) of -507.71%.

However, within the Healthcare sector 1039 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Feb 29 2024 quarter, so far to 5145, from total ROA ranking in the first quarter of 2023 at 5940.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Feb 29 2024) II. Quarter	(Nov 30 2023) I. Quarter	(Aug 31 2023) IV. Quarter	(May 31 2023) III. Quarter	(Feb 28 2023) II. Quarter
Y / Y Total Assets Change	-78.14 %	-98.6 %	-99.83 %	37.14 %	-78.5 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-5	-13	-13	-46	-47
Return On Assets (TTM)	-507.71 %	-1110.33 %	-874.53 %	-371.81 %	-390.88 %
MYYZ's Total Ranking	# 5145	# 5940	# 5309	# 5391	# 5316
Total Assets (TTM) in million	0	0	0	4	1
Seq. Total Assets Change	505.79 %	-73.62 %	-98.08 %	611.92 %	-61.26 %
Seq. Net Income Change	-	-	-	-	-

MYYZ's 5 Years Annual ROA >> Back to MYYZ Management Effectiveness >> Compare MYYZ ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 505
Sector	# 1040
Overall	# 5047

Return On Assets Statistics
High	Average	Low
724.74 %	-311.49 %	-1640.04 %
(Aug 31 2021)		(May 31 2017)

Financial Statements
Innovation1 Biotech Inc 's Assets	$ 0 million	MYYZ's Balance sheet
Innovation1 Biotech Inc 's Income	$ 0 million	Quarterly MYYZ's Income Statement
MYYZ's Income by Division		See MYYZ's Income by Division

Annual Return On Assets	(Aug 31 2023) FY 2023	(Aug 31 2022) FY 2022	(Aug 31 2021) FY 2021	(Aug 31 2020) FY 2020	(Aug 31 2019) FY 2019
Y / Y Total Assets Change	-99.83 %	23816.77 %	-12.82 %	-18.65 %	-70.27 %
Total Assets in million	0	44	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-13	-41	1	-3	0
Annual Return On Assets	-17318.63 %	-93.97 %	571.75 %	-1236.67 %	-66.31 %

MYYZ's 5 Years Annual ROA >> Back to MYYZ Management Effectiveness >> Compare MYYZ ROA to its Competitors

More Return On Assets Ratios
MYYZ's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MYYZ's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MYYZ's Competitors
Subscribers only: Roa for Innovation1 Biotech Inc 's Suppliers
Subscribers only: Return On Assets for MYYZ's Customers

You may also want to know
MYYZ's Roi	MYYZ's Inventory Turnover Ratio	MYYZ's Growth Rates	MYYZ's Dividend Comparisons
	MYYZ's Profitability Ratios	MYYZ's Asset Turnover Ratio	MYYZ's Dividend Growth
MYYZ's Roe	MYYZ's Valuation Ratios	MYYZ's Financial Strength Ratios	MYYZ's Dividend Payout Ratio

Companies with similar Return On Assets at Feb 29 2024, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.